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Purpose: The current methods used to evaluate the efficacy
of drug products are inadequate. We propose a non-inferiority
approach to prove the safety of drugs. Materials and Methods:
Traditional hypotheses for the evaluation of the safety of drugs
are based on proof of hazard, which have proven to be
inadequate. Therefore, based on the concept of proof of safety,
the non-inferiority hypothesis is employed to prove that the
risk of new drugs does not exceed a pre-specified allowable
safety margin, hence proving that a drug has no excessive risk.
The results from papers published on Vioxx and Avandia
are used to illustrate the difference between the traditional
approach for proof of hazard and the non-inferiority approach
for proof of safety. Results: The p-values from traditional
hypotheses were greater than 0.05, and failed to demonstrate
that Vioxx and Avandia are of cardiovascular hazard.
However, these results cannot prove that both Vioxx and
Avandia are of no cardiovascular risk. On the other hand,
the non-inferiority approach can prove that they are of
excessive cardiovascular risk. Conclusion: The non-inferiority
approach is appropriate to prove the safety of drugs.
Key Words: Effectiveness, safety, no excessive risk, non-
inferiority approach
INTRODUCTION
After more than 100 deaths caused by the Elixir
Sulfanilamide disaster in 1938, the US Congress
passed the Federal Food, Drug, and Cosmetic Act
(FD&C Act) which, for the first time in US history,
required pharmaceutical companies to submit full
reports of investigations regarding the safety of
new drugs. However, it was not until 1962, after
the passage of the Leaver-Harris Amendment of
the FD&C Act, that the US Food and Drug
Administration (US FDA) was authorized to
require evidence of efficacy for approval of new
drugs. Consequently, for the approval of a new
drug, the US FDA requires adequate and
controlled clinical trials be conducted on humans
to demonstrate their effectiveness and safety. The
safety of a drug ought to be the primary focus and
should come before its efficacy.
However, there has recently been an alarmingly
increasing trend of safety issues of drugs after
their approval. For instance, the most notorious
example is the withdrawal of Vioxx (rofecoxib)
in 2004 after its excessive cardiovascular risk was
not only confirmed by a retrospective nested case-
control study
1 but also by prospective clinical
trials.
2,3 The most recent safety saga is also the
cardiovascular risk associated with Avandia
(rosiglitazone), one of the most widely used
thiazolidinediones that are agonists for peroxi-
some-proliferator-activated receptor γ (PPAR- . γ
Nissen and Wolski
4 reported a meta-analysis that
showed that the risk of myocardial infarction is
43% higher than that of the control group. These
safety issues reflect that the current evaluation
processes are not adequate for the assessment of
the safety of drugs for approval. Consequently, an
US congressional hearing and an US FDA joint
advisory committee meeting were called on June
6 and July 30, 2007, respectively, to review the
issues surrounding drug safety.
5
As mentioned before, safety comes before
efficacy. However, at least in design, conduct and
analysis of the adequate and well-controlled
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clinical trials, this may not be totally true for
pharmaceutical companies to develop new drugs
and for regulatory agencies to approve them. The
current paradigm for the approval of a new drug
is two-fold. First, the drug must be proven to be
efficacious. Second, it must be verified whether
there is any excessive safety risk even though the
objective is to prove that the drug is safe. As a
result, the selection of study design, endpoints,
statistical methods, and sample size are to maximize
the probability of proving the effectiveness of the
drug. On the other hand, most clinical trials
conducted during the development of the drug do
not select the optimal design with a sufficient
number of patients and correct endpoints to prove
that the drug is safe. In addition, most of the
analyses of safety data are descriptive in nature
and no inferences are made. Consequently, these
trials are neither adequate nor well controlled for
the evaluation of safety.
One of the most critical but often neglected
components during the review process for drug
approval is the statistical evaluation of the
evidence of safety. To prove the effectiveness of
a drug, the approach is to adopt the traditional
hypothesis of equality. In other words, the
effectiveness of a drug is proven by rejecting the
null hypothesis of equal efficacy between the test
drug and control to prove that the alternative
hypothesis of a superior efficacy of the test drug
is true. This approach is adequate for proof of
efficacy of drug products. However, the same
approach is not appropriate for the evaluation of
safety because it is for proof of hazard or
excessive risk of drugs.
6 Therefore, failure to reject
the null hypothesis of no excessive risk cannot
prove that a drug is safe.
7 To prove that a drug
is safe, based on the concept of risk management,
we suggest that the non-inferiority hypothesis
with consideration of managing the magnitude of
the safety risk is more appropriate than the
traditional hypothesis.
MATERIALS AND METHODS
Current approaches
For the sake of illustration, we considered a
situation in which a clinical trial with a randomized
two-group parallel design was conducted to
compare the efficacy and safety of a test drug
with a concurrent control group. Let R denote the
risk ratio (relative risk) or odds ratio of the test
drug compared to the control with respect to a
pre-defined adverse event (AE) such as confirmed
cardiovascular events. Currently, the inference of
safety evaluation is based on the following
traditional hypothesis:
Ho: R 1 vs. Ha: R > 1. (1)
The null hypothesis Ho in equation (1) states
that the risk of the test drug is smaller than that
of the control. On the other hand, the alternative
hypothesis Ha in equation (1) states that the risk
of the test drug is greater than that of the control.
Therefore, the objective of this formulation of the
hypothesis for evaluation of safety is to verify
whether the test drug is of excessive risk with
respect to a pre-defined AE compared to the
control. This approach is referred to as the proof-
of-hazard approach.
6 When the null hypothesis Ho
in equation (1) is rejected at the significance α
level, it can then be concluded that the test drug
is of excessive risk. However, when the null
hypothesis in equation (1) is not rejected, the only
conclusion that can be reached is that the data can
not provide sufficient evidence to doubt the
validity of the null hypothesis.
7 In other words,
failure to reject the null hypothesis does not
necessarily prove the null hypothesis of no
excessive risk in equation (1) and cannot conclude
that the test drug is safe.
The decision based on the hypothesis in
equation (1) is either to reject the null hypothesis
or fail to reject the null hypothesis. Consequently,
another drawback of the formulation of the
hypothesis in equation (1) is its qualitative nature
because it does not take the magnitude of the risk
into consideration. The other two disadvantages
of the hypotheses in equation (1) are well known
in the area of bioequivalence.
8 If a study was
poorly conducted, a non-significant result may be
due to a larger variability associated with the
safety data although that the risk of the test drug
is in fact greater than that of the control.
Furthermore, sample sizes for most drug trials
currently are powered only to demonstrate theApproaches to Evaluating Drug Safety
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efficacy of the test drug and may not provide
sufficient power for evaluation of safety. A
non-significant result regarding the safety does
not prove that the test drug is safe. In summary,
the traditional hypotheses in equation (1) cannot
prove that the drug is safe, and fails to take into
account the magnitude of the risk.
Non-inferiority approach
The objective of the evaluation of safety data for
approval of a new drug is to prove that the drug
is safe. In other words, one should prove that the
test drug poses no excessive risk in the targeted
patient population compared to the control group.
This concept is referred to as the proof of safety.
6
Therefore, we suggest that the inferential
assessment of the safety data is formulated as the
following non-inferiority hypothesis
9
Ho: R > 1 + 0 vs. Ha: R 1+ 0, (2)
where 0 > 0 is some pre-specified safety
margin based on the relative risk.
The alternative hypothesis Ha in equation (2) is
to prove by a clinically allowable and incon-
sequential margin that the risk associated with a
pre-defined adverse event of the test drug is not
greater than that of the control group. Therefore,
the formulation of the non-inferiority hypotheses
manages not only the magnitude of the safety risk
within an acceptable margin but also correctly
expresses the hypothesis of no excessive risk as
the alternative hypothesis Ha in equation (2). It
follows that rejecting the null hypothesis Ho in
equation (2) proves that the test drug is of no
excessive risk.
Statistical methods for testing the non-infer-
iority hypotheses are available and can directly be
applied to the evaluation of the safety of the test
drug.
10-15 However, a more informative way to test
the non-inferiority hypotheses in equation (2) is to
construct a (1 - 2 )100% confidence interval (CI) α
for the risk ratio. If the upper limit of the (1 - 2 ) α
100% CI for the risk ratio is less than the pre-
specified allowable safety margin in the targeted
patient population, then at the significance level, α
the test drug can be concluded of no excessive
risk as compared to the control group. The
confidence interval approach is preferable because
it can test not only the non-inferiority hypotheses
in equation (2) but also provides a quantitative
range of the risk ratio with (1- 2 )100% confidence. α
We applied both the traditional and non-
inferiority hypotheses to the results of the studies
from papers published on Vioxx and Avandia .
For the purpose of illustration of the difference
between the concepts of proof of hazard and proof
of safety, was selected as 2.5% and α 0 in
equation (2) was chosen to be 0.5 for which a 50%
increase of safety risk of the test drug over the
control is clinically allowed.
RESULTS
Graham et al.
1 reported the results of a nested
case control study on cardiovascular risk of
COX-2 inhibitors. This study is based on a claim
database of a national integrated managed care
organization in conjunction with the mortality
status and cause of death from the California
Department of Health and Center for Health
Statistics. Table 1 shows the odds ratios of acute
myocardial infarction with the use of selected
NSAIDs compared to remote use of a NSAID.
Table 1 reveals that the upper limits of the 95%
CI for odds ratios of acute myocardial infarction
for celecoxib and ibuprofen are less than 1.50. It
follows that, with respect to the risk of acute
myocardial infarction, celecoxib and ibuprofen
pose no excessive risk compared to remote users
of NSAIDs. For naproxen, even though the
p-value for the hypothesis in Equation (1) is 0.05,
it can be concluded that naproxen is of no
excessive risk of acute myocardial infarction
compared to remote users of NSAIDs, because the
upper limit of 95% CI for odds ratios of acute
myocardial infarction is less than the upper safety
margin of 1.5. On the other hand, since their
upper limits of all 95% CIs for odds ratios are
larger than the safety margin of 1.5, it cannot be
concluded that rofecoxib is of no excessive risk of
acute myocardial infarction over the remote users
of NSAIDs even though some p-values based on
the hypothesis in equation (1) is greater than 0.05.
Bresalier et al.
3 reported that the risk of
cardiovascular event associated with rofecoxib in
the APPROVe trial, which was a chemopreventionJen-pei Liu
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trial involving 2,586 subjects with colorectoral
adenoma. Table 2 provides the relative risks of
confirmed serious thrombotic events of rofecoxib
compared to the placebo group. Table 2 shows
that although the 95% confidence interval of
relative risk includes 1 between month 0 and
month 18, its upper limit is 2.15, which is greater
than the safety margin of 1.5. Therefore, contrary
to the claim made by the paper, rofecoxib cannot
be concluded to be of no excessive risk with
respect to serious thrombotic events.
Table 3 presents partial results by Nissen and
Wolski
4 who performed a meta-analysis on a
total of 26,000 patients for the effects of Avandia
on the risk of myocardial infarction and death
from cardiovascular causes. As seen in Table 3,
the upper limits of all 95% CIs for odds ratios are
greater than 1.5. Despite the fact that some of the
95% CIs for odds ratios include 1, it cannot be
concluded that Avandia possesses no excessive
risk of myocardial infarction and death from
cardiovascular causes. In response to the meta-
analysis by Nissen and Wolski,
4 Home et al.
16
reported an interim analysis of the RECORD trial
of a total of 4,000 patients with a planned median
follow-up of 6 years for the effect of Avandia on
cardiovascular outcomes. The hazard ratios of
death from cardiovascular causes, acute myocardial
infarction, or congestive heart failure are given in
Table 4. With respect to death from various
causes, the upper limits of all 95% CIs for hazard
ratios are less than 1.5. Therefore, from the data
accumulated at the cut-off date of March 30, 2007,
with a mean follow-up of 3.75 years, Avandia
can be concluded to be of no excessive risk of
death. On the other hand, however, the upper
limits of the 95% CIs of hazard ratios with respect
to acute myocardial infarction, and congestive
heart failure are greater than 1.5. Therefore,
Avandia cannot be claimed to be of no excessive
risk of acute myocardial infarction and congestive
heart failure.
Table 1. Odds Ratios of Acute Myocardial Infarction with Use of Selected NSAIDs Compared with Remote Use
of a NSAID
NSAID Odds ratio 95% C.I. Adjusted p value based on hypothesis in Eq. (1)
Remote use 1
Celecoxib 0.84 (0.67, 1.04) 0.12
Ibuprofen 1.06 (0.96, 1.17) 0.27
Naproxen 1.14 (1.00, 1.30) 0.05
Rofecoxib (all doses) 1.34 (0.98, 1.82) 0.066
Rofecoxib
<= 25 mg/day 1.23 (0.89, 1.71) 0.21
> 25 mg/day 3.00 (1.09, 8.31) 0.03
Adapted from Graham, et al.
1
Table 2. Relative Risks of Confirmed Serious Thrombotic Events of Rofecoxib Compared with Placebo in APPROVe
Trial
Adverse event Relative risk 95% C.I.
Overall all 1.92 (1.19, 3.11)
Month 0 - 18 1.18 (0.64, 2.15)
Month 19 - 36 4.45 (1.77, 13.32)
Adapted from Bresalier, et al.
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DISCUSSION
For approval of a new drug, sponsors and
regulatory agencies must assure that the drug is
safe. However, the continuing saga of emerging
safety problems after approval warrants us to
rethink and review the current approach to
evaluation of the safety data before approval. As
formulated by the traditional hypothesis in
equation (1), the current paradigm for evaluation
of safety is based on the concept of proof of
hazard to detect existence of excessive safety risk
of the new drug. Therefore, failure to reject the
null hypothesis of no excessive risk does not
necessarily prove that the new drug is of no
excessive safety risk and hence cannot guarantee
that it is safe. In addition, the magnitude of safety
risk has not been considered in the traditional
hypotheses in equation (1). As a result, the current
statistical approach to assessing the drug safety is
neither appropriate nor adequate.
The notion that a drug is safe implies that the
drug is of no excessive safety risk in the targeted
patient population. In other words, no excessive
safety risk means that the safety risk of the drug
can not exceed a clinically inconsequential margin
with respect to the control group in the targeted
patient population. Therefore, the non-inferiority
hypothesis with consideration of the magnitude of
the safety risk in equation (2) is more appropriate
Table 3. Risk of Myocardial Infarction and Death from Cardiovascular Causes of Avandia
Study Odds ratio 95% C.I. p value based on hypothesis in Eq. (1)
Myocardial infarction
Small trials combined 1.45 (0.88, 2.39) 0.15
DREAM trial 1.65 (0.74, 3.68) 0.22
ADOPT trial 1.33 (0.80, 2.21) 0.27
Overall 1.43 (1.01, 1.98) 0.03
Death from CV causes
Small trials combined 2.40 (1.17, 4.91) 0.02
DREAM trial 1.20 (0.52, 2.78) 0.67
ADOPT trial 0.80 (0.17, 3.86) 0.78
Overall 1.64 (0.98, 2.74) 0.06
Adapted from Nissen and Wolski.
4
Table 4. Hazard Ratios of Death from Cardiovascular Causes of Avandia in RECORD Trial
Adjudicated events Hazard ratio 95% C.I. p value based on hypothesis in Eq. (1)
Death
From CV causes 0.83 (0.51, 1.36) 0.46
From any cause 0.93 (0.67, 1.27) 0.61
Acute myocardial infarction 1.16 (0.75, 1.81) 0.50
Congested heart failure 2.24 (1.27, 3.97) 0.006
Death from CV causes, myocardial
infarction, and stroke
0.97 (0.73, 1.29) 0.83
Adapted from Home, et al.
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to prove that the drug is of no excessive risk. In
addition, statistical methods for the non-inferiority
hypothesis are available and can directly be
applied to verify the safety of the drug.
The selection of safety margins is an extremely
important issue in the implementation of the
non-inferiority hypothesis for evaluation of safety
of drug products. Safety margins depend on the
seriousness and consequences of the adverse
events, targeted patient population, duration of
intended use, magnitude of effectiveness, desirable
benefit-risk ratio, and many other factors. There-
fore, safety margins should vary depending on
different diseases, classes of drugs, and targeted
patient population. They should be determined
jointly by clinicians, epidemiologists, pharmacists,
statisticians, and other personnel involved in drug
development as well as approval processes from
sponsors, academia, and regulatory agencies.
During phase I and II trials, information on safety
profiles of new drugs can be obtained. Therefore,
for phase III studies, the protocol should specify
the primary safety parameters and safety margins
in addition to the primary efficacy endpoints.
Furthermore, phase III trials should be powered to
verify that the drug is of no excessive risk based
on the non-inferiority hypothesis. Only in this
way, the safety of drugs and patients can be
guaranteed.
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